1 / 10

Authors: de Bono et al, ESMO, October 2010

Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized placebo controlled phase III study. Authors: de Bono et al, ESMO, October 2010

porter
Download Presentation

Authors: de Bono et al, ESMO, October 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized placebo controlled phase III study. Authors: de Bono et al, ESMO, October 2010 Subgroup analysis update: Scher et al, GU ASCO, February 2011 Reviewed by: Dr. Lori Wood Abstract: ESMO LBA5, GU ASCO Abstract 4 Date posted: May 13, 2011

  2. Thank you for downloading this update. Please feel free to use it for educational purposes. Please acknowledge OncologyEducation.ca and Dr. Wood when using these slides.

  3. After patients with metastatic CRPCa fail docetaxel-based chemotherapy, there were no randomized trials showing a clinically significant benefit to any other agents. In Canada, we often treated patients with mitoxantrone based on phase II data. Studies show that CRPCa remains driven by ligand-dependent androgen receptor signaling. Abiraterone acetate (AA) is a potent selective inhibitor of CYP17 which is a key enzyme in androgen synthesis. Basic science and some clinical data suggest that some CRPCa’s remain dependent on androgen receptor signaling. BACKGROUND

  4. STUDY DESIGN Abiraterone Acetate (AA) 1000 mg po qd + Prednisone 5 mg bid n=797 Metastatic CRPCa n=1195 Had to Have Received Prior Docetaxel  Mitoxantrone 1 Outcome = OS 2 Outcomes = PSA Progression, Radiographic Progression, PSA, RR Placebo + Prednisone 5 mg bid n=398

  5. PATIENT CHARACTERISTICS

  6. RESULTS

  7. TOXICITY

  8. SUBGROUP ANALYSIS(GU ASCO 2011) • All subgroups benefited • ECOG: 0-1 vs. 2 • BPI:  4 vs.  4 • Prior chemotherapy: 1 vs. 2 • Progression: PSA only vs. radiological  PSA • LDH: low vs. high

  9. Data reviewed at a pre-specified interim analysis and IDMC recommended study be unblinded. AA shows a 3.8m survival advantage over placebo post docetaxel-based chemotherapy in patients with metastatic CRPCa. Very well-tolerated. STUDY COMMENTARY

  10. BOTTOM-LINE FOR CANADIAN MEDICAL ONCOLOGISTS • This study will change practice. • Results from another post docetaxel phase III trial (TROPIC: Cabazitaxel vs. Mitoxantrone) were reported at ASCO 2010. •  Median OS 15.1m vs. 12.7m • Given the ease of administration and low toxicity, AA will likely become the standard of care post docetaxel-based chemotherapy in men with metastatic CRPCa.

More Related